Recursion Pharmaceuticals, Inc. filings document the regulatory record for a clinical-stage TechBio company advancing investigational medicines through an AI-native discovery and development platform. Its 8-K reports disclose operating results, financial condition, Regulation FD presentations, clinical and pipeline updates, partner milestones and material corporate events.
Proxy materials cover annual-meeting matters, director elections, executive compensation and governance practices. Other filings include leadership-transition disclosures, shelf-registration and prospectus-supplement records for Class A common stock, and capital-structure disclosures tied to shares issued under the Tempus master agreement.
Recursion Pharmaceuticals Inc. insider Blake C. Borgeson filed to sell up to 30,000 Class A shares of RXRX through Fidelity Brokerage Services, with a proposed aggregate sale price of $97,500.00 on August 4, 2026. The shares are identified as founders shares acquired from the issuer as compensation on September 19, 2017. The filing also lists prior Class A share sales over the past three months: 30,000 shares for $105,600.00 on May 5, 2026, 30,000 shares for $110,400.00 on June 2, 2026, and 40,000 shares for $158,500.00 on July 7, 2026.
A shareholder of RXRX, identified as Christopher C. Gibson, filed a Form 144 indicating a proposed sale of 75,000 Class A shares through Fidelity Brokerage Services LLC on August 4, 2026, with an approximate aggregate market value of $244,875.00.
The shares to be sold are described as Founders Shares acquired from the issuer on April 20, 2021 as compensation. The filing also lists extensive Class A share sales during the past three months by Christopher C. Gibson and related entities, including transactions such as 340,440 shares sold for $1,089,541.29 on June 18, 2026, and multiple 100,000-share blocks sold on various dates in July 2026, along with additional sales by the Gibson Family Trust and Lahwran-3 LLC.
Vanguard Portfolio Management LLC, together with certain affiliates, reports beneficial ownership of 31,369,274 shares of Recursion Pharmaceuticals Inc. common stock on a passive ownership basis. This represents 5.97% of the class as of June 30, 2026.
Vanguard has sole voting power over 237,675 shares and sole dispositive power over 31,369,274 shares, with no shared voting or dispositive power. The position reflects securities held by Vanguard funds and managed accounts, and no other single person’s interest in these securities exceeds 5% of the class.
Vanguard Capital Management LLC, together with specified affiliates, reports beneficial ownership of 26,744,129 shares of Recursion Pharmaceuticals Inc. common stock on a Schedule 13G. This represents 5.09% of the class as of June 30, 2026.
Vanguard has sole voting power over 3,978,189 shares and sole dispositive power over all 26,744,129 shares, with no shared voting or dispositive power. The position includes securities held by Vanguard funds and managed accounts over which Vanguard entities exercise voting and/or dispositive power. Dividends and sale proceeds are generally for the benefit of those funds and managed-account clients, and no other single person is reported to have an interest in more than 5% of the class.
RXRX received a Rule 144 notice for a proposed sale of 75,000 Class A shares through Fidelity Brokerage Services LLC on 07/30/2026, with an aggregate value of $225,000.29 on NASDAQ. These shares were acquired on 04/20/2021 as Founders Shares for compensation. The filing also lists numerous prior Class A share sales during May–July 2026 by Christopher C. Gibson and affiliated entities, each with specified share counts and dollar amounts.
A shareholder of RXRX, including entities associated with Christopher C. Gibson, filed to sell 50,000 Class A shares through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate value of $151,371.91. The shares are described as Founders Shares originally acquired from the issuer as compensation on April 20, 2021. The filing also lists multiple prior Class A share sales by Gibson, Gibson Family Trust, and Lahwran-3 LLC over the past three months, each with specified share counts, dates, and dollar amounts.
BlackRock, Inc. filed an amended Schedule 13G reporting passive ownership of Class A stock of Recursion Pharmaceuticals, Inc. (RXRX). BlackRock and certain of its business units are deemed to beneficially own 44,541,605 shares of Class A stock, representing 8.5% of the class.
BlackRock reports sole voting power over 43,812,201 shares and sole dispositive power over 44,541,605 shares, with no shared voting or dispositive power. Various underlying clients and investors have rights to dividends or sale proceeds, but no single person has more than five percent of the outstanding common shares.
The filing reports that Christopher C. Gibson plans to sell 50,000 Class A shares of RXRX through Fidelity Brokerage Services LLC on NASDAQ, with an indicated aggregate value of $152,702.73. These shares were originally acquired on 04/20/2021 as founders shares received as compensation.
It also lists multiple prior sales of Class A shares in the past three months by Christopher C. Gibson, the Gibson Family Trust, and Lahwran-3 LLC, including several transactions of 100,000 shares and one of 340,440 shares, each with stated aggregate sale proceeds.
A shareholder of RXRX has filed a notice to sell up to 100,000 Class A shares through Fidelity Brokerage Services, with an aggregate market value of $304,262.54, on or after July 21, 2026 on NASDAQ. The shares are identified as Founders Shares originally issued on April 20, 2021 as compensation. The filing also lists numerous prior Class A sales over the past three months by Christopher C. Gibson and related entities, including individual transactions as large as 340,440 shares.
A reporting person associated with RXRX filed a Form 144 indicating an intent to sell 100,000 Class A shares through Fidelity Brokerage Services on 07/20/2026, with an aggregate market value of $289,766.37. The notice identifies these as founders shares originally acquired on 04/20/2021 as compensation from the issuer. It also lists multiple prior Class A share sales over the past three months by Christopher C. Gibson, Gibson Family Trust, and Lahwran-3 LLC, each with specific dates, share amounts, and dollar proceeds.